Side-by-side · Research reference

GHRP-2vsSemaglutide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2Reviewed15/42 cited

BFDA-ApprovedVerified15/53 cited

GHRP-2

Hexapeptide GHRP · Phase 2 (clinical diagnostic)

100–300 mcgPer doseBowers 1990

Phase 2Evidence levelBowers 1990 Sigalos 2018

~30 minHalf-lifeMalagón 1999

SQ · Multiple sites · 1–3×/day

Semaglutide

GLP-1 RA · FDA-Approved

0.25–2.4 mgWeekly doseWEGOVY (semaglutide) injection 2021

14.9%Body-weight ↓Wilding 2021

~7 daysHalf-lifeWEGOVY (semaglutide) injection 2021

SQ · Abdomen / thigh / arm · Once weekly

01Mechanism of Action

Parameter

GHRP-2

Semaglutide

Primary target

Ghrelin receptor (GHS-R1a) on anterior pituitaryBowers 1990

GLP-1 receptor (GLP-1R)WEGOVY (semaglutide) injection 2021

Pathway

GHS-R1a → Gαq → Ca²⁺ → GH vesicle exocytosisBowers 2002

GLP-1R agonism → ↑glucose-dependent insulin secretion, ↓glucagon, ↓gastric emptying, ↓appetite via hypothalamic centresWilding 2021

Downstream effect

Strong GH pulse + IGF-1 elevation; appetite increase via ghrelin agonismBowers 2002

Improved glycemic control, reduced caloric intake, body-weight reduction, cardiovascular risk reductionWilding 2021

Feedback intact?

Yes, with somatostatin feedback active

Glucose-dependent insulin release preserves physiological feedback

Origin

Synthetic hexapeptide; developed by Bowers/Tulane group in the 1980sBowers 1990

Modified GLP-1(7-37) with two amino-acid substitutions and C-18 fatty-acid acylation for albumin binding and 168-h half-lifeWEGOVY (semaglutide) injection 2021

Antibody development

—

02Dosage Protocols

Parameter

GHRP-2

Semaglutide

Standard dose

100–300 mcg per injectionBowers 1990

—

Frequency

1–3× per day

Once weekly, same day each week

Lower / starter dose

50 mcg per dose

—

Evidence basis

Phase 2 + clinical diagnostic useBowers 1990

FDA-approved · Phase 3 RCTsWilding 2021 WEGOVY (semaglutide) injection 2021

Duration

8–12 weeks on / 4 off (anecdotal)

Indefinite for chronic indication

Discontinuation results in weight regain.

Reconstitution

Bacteriostatic water

Pre-mixed pen device (commercial). Research lyophilised vial: bacteriostatic water per label.

Timing

Pre-sleep + fasted preferred

Any time of day, with or without food

Half-life

~30 minMalagón 1999

~7 days (168 h)WEGOVY (semaglutide) injection 2021

Standard dose (T2D, Ozempic)

—

0.5–1.0 mg / weekWEGOVY (semaglutide) injection 2021

Standard dose (weight, Wegovy)

—

2.4 mg / week (after 16-wk titration)WEGOVY (semaglutide) injection 2021 Wilding 2021

Titration schedule

—

0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks

Mitigates GI side effects.

04Side Effects & Safety

Parameter

GHRP-2

Semaglutide

Cortisol elevation

Mild but measurableBowers 1990

—

Prolactin elevation

Mild but measurable

—

Hunger

Strong appetite increase

—

Injection site reaction

Mild erythema

Mild erythema, pruritus

IGF-1 elevation

Strong; monitor with chronic high-dose use

—

Cancer risk

Contraindicated in active malignancy

—

Pregnancy / OB

Avoid

ContraindicatedWEGOVY (semaglutide) injection 2021

GI symptoms

—

Nausea, vomiting, diarrhea, constipation (very common)Wilding 2021

Pancreatitis risk

—

Rare; discontinue if suspectedWEGOVY (semaglutide) injection 2021

Thyroid C-cell tumours

—

Boxed warning — contraindicated in MEN2 / personal or family MTC historyWEGOVY (semaglutide) injection 2021

Hypoglycemia

—

Low risk as monotherapy; elevated when combined with sulfonylureas / insulin

Gallbladder events

—

Increased cholelithiasis

Heart rate

—

Modest ↑ resting HR (~2-4 bpm)

Absolute Contraindications

GHRP-2

·Active malignancy
·Pregnancy / breastfeeding

Semaglutide

·Personal or family history of medullary thyroid carcinoma
·Multiple endocrine neoplasia syndrome type 2
·Pregnancy / breastfeeding
·Hypersensitivity to semaglutide

Relative Contraindications

GHRP-2

·Untreated diabetes

Semaglutide

·Severe gastroparesis
·History of pancreatitis
·Diabetic retinopathy (may worsen with rapid glycemic improvement)

05Administration Protocol

Parameter

GHRP-2

Semaglutide

1. Reconstitution

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.

Commercial: pre-filled pen, no reconstitution. Research vial: per-label or bacteriostatic water.

2. Injection site

SQ — abdomen or thigh. Rotate sites.

SQ — abdomen, thigh, or upper arm. Rotate sites weekly to avoid lipohypertrophy.

3. Timing

Pre-sleep + fasted preferred.

Once weekly, same day. Day can be changed if ≥2 days separate doses.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

Pen: refrigerate 2–8 °C unopened; room temp ≤30 °C up to 56 days after first use.

5. Needle

29–31G, 4–8 mm insulin syringe.

Pen-supplied 31–34G needle. Research vial: 27–31G insulin syringe.

06Stack Synergy

GHRP-2

+ CJC-1295 (no DAC)

Strong

View CJC-1295 (no DAC) →

GHRP-2 + CJC-1295-no-DAC is a higher-amplitude alternative to the ipamorelin + CJC-1295 stack. GHRP-2 produces a stronger pulse but with cortisol + prolactin signal — choose when maximum GH amplitude is the goal and the side-effect tolerance is acceptable.

GHRP-2: 100–200 mcg SQ · pre-sleep
CJC-1295 (no DAC): 100 mcg SQ · same injection
Primary benefit: High-amplitude GH pulse, body composition

Bowers 1990 Teichman 2006

Semaglutide

+ Tirzepatide

Weak

View Tirzepatide →

Combining two GLP-1 RA-class drugs is not clinically validated and risks additive GI toxicity. Tirzepatide's GIP component already provides complementary mechanism vs pure GLP-1; stacking with semaglutide adds receptor saturation but no synergy. NOT recommended.

Note: Stack not recommended — choose one GLP-1 RA
Primary benefit: (none — additive toxicity, no synergy)